用于治疗多发性硬化症的新型及新兴免疫靶向药物。
New and emerging immune-targeted drugs for the treatment of multiple sclerosis.
作者信息
Palmer Alan M
机构信息
MS Therapeutics Ltd, Crowthorne, Berks, RG45 7AW, UK; Department of Research and Enterprise Development, University of Bristol, Bristol, BS8 1TH, UK.
出版信息
Br J Clin Pharmacol. 2014 Jul;78(1):33-43. doi: 10.1111/bcp.12285.
Multiple sclerosis (MS) is a neurodegenerative disease with a major inflammatory component that constitutes the most common progressive and disabling neurological condition in young adults. Injectable immunomodulatory medicines such as interferon drugs and glatiramer acetate have dominated the MS market for over the past two decades but this situation is set to change. This is because of: (i) patent expirations, (ii) the introduction of natalizumab, which targets the interaction between leukocytes and the blood-CNS barrier, (iii) the launch of three oral immunomodulatory drugs (fingolimod, dimethyl fumarate and teriflunomide), with another (laquinimod) under regulatory review and (iv) a number of immunomodulatory monoclonal antibodies (alemtuzumab, daclizumab and ocrelizumab) about to enter the market. Current and emerging medicines are reviewed and their impact on people with MS considered.
多发性硬化症（MS）是一种具有主要炎症成分的神经退行性疾病，是年轻成年人中最常见的进行性致残性神经系统疾病。在过去二十年中，诸如干扰素药物和醋酸格拉替雷等可注射免疫调节药物在MS市场占据主导地位，但这种情况即将改变。原因如下：（i）专利到期；（ii）那他珠单抗的推出，其靶向白细胞与血脑屏障之间的相互作用；（iii）三种口服免疫调节药物（芬戈莫德、富马酸二甲酯和特立氟胺）的上市，另一种药物（拉喹莫德）正在接受监管审查；（iv）一些免疫调节单克隆抗体（阿仑单抗、达利珠单抗和奥瑞珠单抗）即将进入市场。本文对现有和新兴药物进行了综述，并考虑了它们对MS患者的影响。
Zotero 插件